Claims
- 1. A compound represented by the following structural formula:
- 2. The compound of claim 1, wherein n is 5.
- 3. The compound of claim 1, wherein R1 is a substituted or unsubstituted heteroaryl group, phenyl group or naphthyl group.
- 4. The compound of claim 1, wherein R1 is a substituted or unsubstituted pyridyl group, quinolinyl group or isoquinolinyl group.
- 5. The compound of claim 1, wherein R1 is a substituted or unsubstituted phenyl group.
- 6. The compound of claim 5, wherein R1 is an unsubstituted phenyl group.
- 7. The compound of claim 6, wherein n is 5.
- 8. The compound of claim 1, wherein R1 is an unsubstituted pyridyl group.
- 9. The compound of claim 8, wherein R1 is β-pyridyl.
- 10. The compound of claim 9, wherein n is 5.
- 11. The compound of claim 1, wherein R1 is an unsubstituted quinolinyl group.
- 12. The compound of claim 11, wherein R1 is a 2-quinolinyl group.
- 13. The compound of claim 12, wherein n is 5.
- 14. The compound of claim 1, wherein R1 is a substituted or unsubstituted arylalkyloxy group.
- 15. The compound of claim 14, wherein R1 is substituted or unsubstituted benzyloxy group.
- 16. The compound of claim 15, wherein R1 is an unsubstituted benzyloxy group.
- 17. The compound of claim 16, wherein n is 5.
- 18. A compound represented by the following structural formula:
- 19. The compound of claim 18, wherein Q1 is an 8-quinolinyl group.
- 20. The compound of claim 18 wherein the pyridyl group is β-pyridyl.
- 21. The compound of claim 20 wherein Q1 is an 8-quinolinyl group.
- 22. The compound of claim 21, wherein n is 5.
- 23. A compound represented by the following structural formula:
- 24. The compound of claim 23, wherein Q1 is an 8-quinolinyl group.
- 25. The compound of claim 23, wherein Q2 is a 2-quinolinyl group.
- 26. The compound of claim 25, wherein Q1 is an 8-quinolinyl group.
- 27. The compound of claim 26, wherein n is 5.
- 28. A compound represented by the following structural formula:
- 29. The compound of claim 28, wherein R1 is a benzyl group.
- 30. The compound of claim 29, wherein R2 is a substituted or unsubstituted quinolinyl group.
- 31. The compound of claim 30, wherein R2 is an unsubstituted quinolinyl group.
- 32. The compound of claim 31, wherein R2 is a 2-quinolinyl group.
- 33. The compound of claim 32, wherein n is 5.
- 34. The compound of claim 29, wherein R2 is a substituted or unsubstituted arylalkyloxy group.
- 35. The compound of claim 34, wherein R2 is a substituted or unsubstituted benzyloxy group.
- 36. The compound of claim 35, wherein R2 is an unsubstituted benzyloxy group.
- 37. The compound of claim 36, wherein n is 5.
- 38. The compound of claim 29, wherein R2 is a substituted or unsubstituted phenyl group.
- 39. The compound of claim 38, wherein R2 is an unsubstituted phenyl group.
- 40. The compound of claim 39, wherein n is 5.
- 41. The compound of claim 29, wherein R2 is a substituted or unsubstitued pyridyl group.
- 42. The compound of claim 41, wherein R2 is an unsubstituted pyridyl group.
- 43. The compound of claim 42, wherein R2 is a β-pyridyl group.
- 44. The compound of claim 43, wherein n is 5.
- 45. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of any of claims 1, 18, 23, and 28, and a pharmaceutically acceptable carrier.
- 46. A method of treating cancer in a subject in need of treatment comprising administering to said subject a therapeutically effective amount the compound of any one of claims 1, 18, 23, and 28.
- 47. A method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an effective amount of the compound of any one of claims 1, 18, 23, and 28.
- 48. A method of selectively inducing cell growth arrest of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an effective amount of the compound of any one of claims 1, 18, 23, and 28.
- 49. A method of selectively inducing apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an effective amount of the compound of any one of claims 1, 18, 23, and 28.
- 50. A method of inducing terminal differentiation of tumor cells in a tumor comprising contacting the cells with an effective amount of the compound of any one of claims 1, 18, 23, and 28.
- 51. A method of inhibiting the activity of histone deacetylase comprising contacting the histone deacetylase with an effective amount of the compound of any one of claims 1, 18, 23, and 28 so as to inhibit the activity of histone acetylase.
- 52. A method of treating a thioredoxin (TRX)-mediated disease in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of the compound of any one of claims 1, 18, 23, and 28.
- 53. The method according to claim 52, wherein said TRX-mediated disease is an inflammatory disease, an allergic disease, an autoimmune disease, a disease associated with oxidative stress or a disease characterized by cellular hyperproliferation.
- 54. A method of treating a disease of the central nervous system in an individual in need thereof comprising administering to the individual a therapeutically effective amount of the compound of any one of claims 1, 18, 23, and 28.
- 55. The method according to claim 54, wherein the disease is a polyglutamine expansion disease.
RELATED APPLICATION
[0001] This application claims the benefit of U.S. Application Ser. No. 60/459,826, filed Apr. 1, 2003, the contents of which are hereby incorporated by reference herein in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60459826 |
Apr 2003 |
US |